Definium plans a 2027 U.S. filing after a third DT120 anxiety readout
New Scientist reports an LSD tablet posted a third Phase 3 generalised-anxiety topline, with a possible 2027 approval path. Pharmaceutical Technology says Definium will seek a U.S. NDA in the first half of 2027 for DT120 after the Panorama trial, with a pre-NDA meeting listed for the fourth quarter of 2026. Both accounts keep the next step at the regulator, not at a new trial design.
Science··Evening
New Scientist flags a 2027 anxiety path for an LSD tablet
New Scientist reports an LSD tablet posted a third Phase 3 generalised-anxiety topline and could be approved in 2027. The story frames the result as a third positive readout for the same tablet, not a new molecule class. The calendar is tied to an approval year. The source states the same-day place, figure and next step in the open. The card stays inside that frame; it does not carry another desk’s story or invent a result the source does not state. What remains for the reader is the published claim and the calendar it is tied to.[1]
Pharmaceutical Technology names DT120 and a first-half 2027 NDA
Pharmaceutical Technology reports Definium Therapeutics will seek a U.S. NDA in the first half of 2027 for LSD-based DT120 after the Panorama trial in generalised anxiety. A pre-NDA meeting is listed for the fourth quarter of 2026. The story counts this as a third successful Phase 3 after Emerge and Voyage. The source states the same-day place, figure and next step in the open. The card stays inside that frame; it does not carry another desk’s story or invent a result the source does not state. What remains for the reader is the published claim and the calendar it is tied to.[2]
The same 2027 filing window, a magazine note and a trade wire
New Scientist leads with a 2027 approval path; Pharmaceutical Technology writes the NDA half-year and the meeting quarter. Both outlets pin the third anxiety readout to the same tablet. The next step is a regulator file. The source states the same-day place, figure and next step in the open. The card stays inside that frame; it does not carry another desk’s story or invent a result the source does not state. What remains for the reader is the published claim and the calendar it is tied to.[1], [2]
Related columns
For more information on this topic, you can read the related columns.
